脑瘤药物市场（按适应症、药物类别、给药途径、最终用户和分销管道）—2025-2032 年全球预测

预计到 2032 年脑癌药物市场规模将成长至 39.3 亿美元，复合年增长率为 7.64%。

主要市场统计数据
基准年2024年	21.8亿美元
预计2025年	23.4亿美元
预测年份：2032年	39.3亿美元
复合年增长率（%）	7.64%

在快速的科学和商业性变革中製定脑癌治疗的当前策略背景

脑肿瘤治疗是肿瘤学中备受关注的领域，其驱动力来自亟待满足的医疗需求和不断加速的科学创新。临床复杂性、血脑障壁障壁挑战、诊断异质性以及监管环境的复杂变化，需要整合分子生物学、给药技术和临床试验设计能力，才能达到转化成功。最近的进展已将治疗套件从细胞毒性药物扩展到生物製药、细胞疗法以及旨在调节肿瘤微环境和免疫反应的标靶小分子。

从商业性角度来看，相关人员必须在高昂的开发成本、漫长的临床路径与特定病患群体获得持续临床效益的潜力之间取得平衡。付款人和卫生技术评估机构越来越重视真实世界证据和基于价值的合同，这更加重视核准后证据的生成和灵活的报销安排。因此，策略规划强调产品组合多元化、与监管机构和付款人的早期合作，以及对伴随诊断和新型给药平台的投资，以最大限度地提高临床和商业性成功的可能性。

总的来说，引言强调了推进尖端科学的双重挑战，同时务实地解决商业化、获取和交付挑战，以确保创新技术转化为积极的患者结果。

这是一个重大变革时期，将重新定义脑瘤药物的整个治疗方法和商业模式

近期趋势表明，一些变革性变化正在改变开发者、临床医生和支付者对脑肿瘤治疗的态度。精准肿瘤学利用分子谱识别可治疗的变异，并为患者选择策略提供信息，它已经改变了临床试验设计，使生物标誌物主导的适应症成为可能，并从概念走向实践。同时，免疫疗法也日益成熟，癌症疫苗、CAR-T疗法和查核点抑制剂正在中枢神经系统适应症的测试中。

同时，包括单株抗体和蛋白酪氨酸激酶抑制剂在内的标靶治疗已透过创新的製剂策略和给药载体适应了血脑障壁的限制。止吐药和生长因子等支持性治疗已成为患者综合管理、提高耐受性和持续进行第一线治疗的关键。数位健康、先进影像技术和液态切片的作用也得到了扩展，使得对疾病进展和治疗反应的动态监测成为可能。总而言之，这些转变需要新的营运模式、与诊断合作伙伴建立协作生态系统，并更加重视产生上市后证据以证明长期效益和价值。

评估 2025 年美国关税对脑癌治疗药物供应链、定价和策略采购的累积影响

关税的征收给跨境供应链中的製药商、委託製造和经销商带来了新的考虑。关税变化可能会改变从国际供应商采购的活性药物原料药和辅料的相对成本结构，迫使企业重新评估供应商多元化、近岸外包和库存策略。由于许多脑肿瘤治疗依赖专门的原料、生物成分和与设备相关的输送系统，因此投入成本的增加可能会透过製造时间表和合约定价结构产生连锁反应。

此外，关税将影响临床试验物流和临床实验药物在临床实验地点之间的流动，可能增加管理费用，并需要提前製定紧急时应对计画。付款人和采购团队可能会透过收紧处方笺或强调成本效益数据来应对成本基准的变化，从而凸显证明临床价值差异的重要性。为此，产业相关人员正在采取各种策略，例如重新谈判供应商合约、将生产转移到关税优惠的司法管辖区以及加速关键投入的在地化。最终，供应链的弹性和策略性采购决策在市场上占据重要地位，成功的公司会优先考虑灵活透明的成本模型，以减轻关税带来的干扰。

按适应症、药物类别、给药途径、最终用户和分销管道进行细分，可提供影响策略重点的见解

多形性胶质母细胞瘤因其侵袭性生物学特性而存在大量未满足的医疗需求，而脑膜瘤、转移性脑瘤和脑下垂体瘤则各自需要不同的治疗方法和调控途径。了解这些临床差异可以改善标靶选择和试验设计。烷化剂、抗代谢物和植物碱等药物类别提供细胞毒机制，突显了某些方案中化疗的基本支柱。同时，包括癌症疫苗、CAR-T 疗法和查核点抑制剂在内的化疗提供了免疫介导的策略，可能在特定群体中产生持久的反应。包括止吐药和生长因子在内的支持性治疗在维持治疗强度和患者生活品质方面发挥重要作用。标靶治疗，包括单株抗体和蛋白酪氨酸激酶抑制剂，能够精确标靶化致癌驱动因子和讯号通路。

按给药途径（鞘内、静脉、口服）进行细分，可以考虑配方开发、患者依从性和设施要求，并有助于确定门诊病人和住院给药模式。按最终用户（如诊所、家庭医疗保健和医院）进行细分，可以为营运规划提供信息，包括输液能力、家庭给药通讯协定和多学科团队的培训需求。按分销管道进行细分，可以区分医院药房、线上药房和零售药房，每种药房都有其独特的合规性、低温运输和报销接触点，从而影响打入市场策略。整合这些细分市场使相关人员能够优先考虑资源分配、完善临床开发计划，并使商业化方法与交付和存取的营运现实保持一致。

美洲、欧洲、中东和非洲以及亚太地区的区域动态和竞争格局塑造了市场进入和伙伴关係策略

由于法律规范、研究架构、临床研究能力和医疗保健基础设施的差异，区域动态存在显着差异。在美洲，成熟的卓越中心和强大的临床试验网络支持新疗法的早期应用，并促进快速患者累积，而付款方越来越需要来自真实世界临床试验结果的证据。在欧洲、中东和非洲，监管协调和国家卫生技术评估流程需要细緻的市场进入规划和长期卫生经济模型，以确保药物纳入处方集。在亚太地区，对癌症研究的快速投资、医院容量的扩大以及本地製造能力的提升，既带来了规模化发展的机会，也带来了与异质监管途径和定价环境相关的复杂性。

与学术中心和合约研究机构的合作支持在已开发市场进行转化研究，而与区域经销商和本地製造商的合作则有助于进入市场，因为本地生产或熟悉监管机构具有优势。临床应用受到诊断能力和护理标准实施差异的影响，这可能会影响生物标记主导疗法的采用速度。因此，针对特定区域制定的策略，考虑到监管时机、报销途径和当地临床实践，对于有效部署脑肿瘤疗法至关重要。

主要企业洞察

领先的製药和生物技术公司正在加强多个领域的能力，以保持脑癌治疗的势头。研发投资日益着重于增强中枢神经系统渗透性的平台、生物标记主导的病患选择，以及标靶药物与免疫调节剂合併用药的联合策略。各公司正透过专业的生产能力（包括病毒载体和细胞疗法生产）实现差异化，并透过与诊断开发商的策略合作伙伴关係共同开发伴随检测，以实现精准註册和标籤差异化。

共同研究模式明显反映创新者、受託製造厂商、学术中心和生物技术合作伙伴之间建立风险共担联盟的趋势。这些模式有助于获取专业技能，加速早期开发，并降低后期专案的风险。产品组合策略强调在新的作用机制与现有资产之间取得​​平衡，以提高耐受性和疗效持久性。此外，业务拓展活动也越来越强调对有前景的早期资产进行授权，以及有针对性地收购互补的给药技术和诊断能力。总体而言，成功的组织会展示由策略外部伙伴关係关係支持的综合临床、监管和商业计划。

为行业领导者提供切实可行的建议，以加强开发平臺、上市和以患者为中心的交付模式

行业领导者应优先考虑与监管机构和付款方进行早期和反覆的沟通，以就证据要求和可接受的终点达成一致，从而反映有意义的临床益处。对伴随诊断和标准化生物标记检测法的投资将提高临床试验效率，并支持有针对性的标籤声明。在营运方面，加强供应链冗余并寻求区域製造伙伴关係可以降低关税和物流风险，并加快临床实验药物的临床应用时间。

公司还应设计开发项目，建立强大的真实世界证据路径，包括註册研究和核准后研究，以支持持久的报销协议。除了疗效之外，强调耐受性和生活品质将向临床医生和付款人展示其价值。与家庭医疗保健提供者和医院合作制定安全的给药通讯协定，将扩大药物的可近性并减轻患者的治疗负担。最后，采用灵活的商业模式，例如结果挂钩合约和在地化定价策略，可以促进不同医疗保健系统的药物可及性，同时确保商业性永续性。

透明的调查方法，解释报告研究结果所依据的资料来源、分析方法和检验过程

调查方法整合了原始研究和二手资料，以实现全面覆盖和洞察检验。原始研究包括对临床研究人员、肿瘤药剂师、付款人、医院采购负责人和行业高管的结构化访谈，并辅以与咨询委员会的磋商，以确定实践模式和应用障碍。二手资料包括同行评审文献、监管文件、临床试验註册中心、会议记录和公司披露信息，以揭示技术趋势、作用机制研发和监管先例。

分析方法包括定性主题分析（用于整合相关利益者的观点）和定量横断面分析（用于考察不同细分市场和地区的应用模式）。为了减少偏误并确认研究结果，我们采用了资料来源三角检定和迭代同侪检验。本调查方法承认临床情况不断发展以及新科学进展与同行评审证据之间可能存在的滞后性，因此强调结论旨在为战略决策提供信息，而非提供规范的临床指导。

整合临床前景、商业性现实和对脑癌治疗利害关係人的策略重要性的结论总结

总而言之，脑癌治疗领域前景光明，但同时也面临复杂的开发和商业化挑战。精准医疗、免疫疗法和给药科学的发展拓展了治疗策略的选择，但成功的临床转化需要临床开发、诊断、生产和支付方参与等方面的协调努力。供应链压力和关税趋势正在推动策略采购和本地生产的考虑，而法规和报销制度的地区差异则要求制定量身定制的上市方案。

我们将设计基于生物标记的临床试验，投资伴随诊断和真实世界证据，增强生产和分销的韧性，并寻求能够实现互补的合作伙伴关係。透过将临床创新与卓越营运和以付款人为中心的证据产生相结合，相关人员可以改善患者获得有效治疗的可及性，并在整个治疗生态系统中创造永续的价值。

目录

第一章：前言

第二章调查方法

第三章执行摘要

第四章 市场概况

第五章 市场洞察

• 将次世代定序生物标记整合到个人化胶质瘤治疗选择中
• 对流增强输送系统在局部脑肿瘤治疗的应用日益增多
• 復发性神经胶母细胞瘤血脑障壁渗透性小分子抑制剂的开发
• 溶瘤病毒合併免疫查核点抑制剂治疗脑肿瘤的临床进展
• 针对多种胶质瘤抗原的双特异性抗体构建体的投资激增，有望改善治疗效果
• 引入人工智慧演算法优化脑肿瘤放射治疗计画和监测

第六章：2025年美国关税的累积影响

第七章：人工智慧的累积影响，2025年

第八章脑肿瘤药物市场（按适应症）

• 多形性胶质母细胞瘤
• 脑膜瘤
• 转移性脑瘤
• 脑下垂体瘤

第九章脑瘤药物市场（依药物类别）

• 化疗
  • 烷化剂
  • 抗代谢物
  • 植物生物碱
• 免疫疗法
  • 癌症疫苗
  • CAR-T疗法
  • 查核点抑制剂
• 支持性护理
  • 止吐药
  • 生长因子
• 标靶治疗
  • 单株抗体
  • 蛋白酪氨酸激酶抑制剂

第 10 章脑肿瘤药物市场（依给药途径）

• 椎管内
• 静脉
• 口服

第 11 章脑肿瘤药物市场（依最终使用者）

• 诊所
• 家庭医疗保健
• 医院

第十二章脑肿瘤药物市场（依通路）

• 医院药房
• 网路药局
• 零售药局

第十三章脑瘤药物市场（按地区）

• 美洲
  • 北美洲
  • 拉丁美洲
• 欧洲、中东和非洲
  • 欧洲
  • 中东
  • 非洲
• 亚太地区

第十四章脑肿瘤药物市场（依类别）

• ASEAN
• GCC
• EU
• BRICS
• G7
• NATO

第十五章脑瘤药物市场（按国家）

• 美国
• 加拿大
• 墨西哥
• 巴西
• 英国
• 德国
• 法国
• 俄罗斯
• 义大利
• 西班牙
• 中国
• 印度
• 日本
• 澳洲
• 韩国

第十六章竞争格局

• 2024年市占率分析
• 2024年FPNV定位矩阵
• 竞争分析
  • F. Hoffmann-La Roche Ltd
  • Merck & Co., Inc.
  • Bristol-Myers Squibb Company
  • Novartis AG
  • Pfizer Inc.
  • Johnson & Johnson
  • Bayer Aktiengesellschaft
  • AbbVie Inc.
  • Teva Pharmaceutical Industries Ltd
  • Amgen Inc.

The Brain Cancer Drugs Market is projected to grow by USD 3.93 billion at a CAGR of 7.64% by 2032.

KEY MARKET STATISTICS
Base Year [2024]	USD 2.18 billion
Estimated Year [2025]	USD 2.34 billion
Forecast Year [2032]	USD 3.93 billion
CAGR (%)	7.64%

Framing the Current Strategic Context for Brain Cancer Therapeutics Amid Rapid Scientific and Commercial Change

The introduction positions brain cancer drugs as a high-priority area within oncology, driven by an urgent unmet medical need and accelerating scientific innovation. Clinical complexity, blood-brain barrier challenges, diagnostic heterogeneity, and regulatory expectations together create a landscape where translational success requires integrated capabilities across molecular biology, delivery technologies, and clinical trial design. Recent advances have expanded the therapeutic toolkit beyond cytotoxic agents to include biologics, cell therapies, and targeted small molecules that aim to modulate tumor microenvironments and immune responses.

From a commercial perspective, stakeholders must balance high development costs and protracted clinical pathways with the potential for durable clinical benefit in select patient populations. Payers and health technology assessment bodies are increasingly focused on real-world evidence and value-based contracting, which places a premium on post-approval evidence generation and adaptive reimbursement arrangements. Consequently, strategic planning now emphasizes diversified portfolios, earlier engagement with regulators and payers, and investment in companion diagnostics and novel delivery platforms to maximize the probability of clinical and commercial success.

Taken together, the introduction highlights the dual imperative: advancing cutting-edge science while pragmatically addressing commercialization, access, and delivery challenges to ensure that innovations translate into meaningful patient outcomes.

Major Transformative Shifts Redefining Treatment Approaches and Commercial Models Across Brain Cancer Therapeutics

Over recent years, several transformative shifts have altered how developers, clinicians, and payers approach brain cancer drugs. Precision oncology has moved from concept to practice as molecular profiling identifies actionable alterations and informs patient selection strategies, thereby changing clinical trial designs and enabling biomarker-driven indications. Concurrently, immunotherapeutic modalities have matured, with cancer vaccines, CAR-T approaches, and checkpoint inhibitors being tested in central nervous system indications; these modalities have prompted reconsideration of combination regimens and novel endpoints suited to immunologic mechanisms.

At the same time, targeted therapies, including monoclonal antibodies and tyrosine kinase inhibitors, have adapted to constraints imposed by the blood-brain barrier through innovative formulation strategies and delivery tools, which include both systemic modifications and localized administration methods. Supportive therapies, such as anti-emetics and growth factors, have become integral to comprehensive patient management, improving tolerability and enabling sustained delivery of primary agents. The role of digital health, advanced imaging, and liquid biopsies has also expanded, enabling more dynamic monitoring of disease trajectory and therapy response. Collectively, these shifts demand new operational models, collaborative ecosystems with diagnostic partners, and an increased emphasis on post-market evidence generation to demonstrate long-term benefit and value.

Assessing the Cumulative Impact of United States Tariffs in 2025 on Supply Chains, Pricing, and Strategic Sourcing in Brain Cancer Therapeutics

The imposition of tariffs has introduced new considerations for pharmaceutical manufacturers, contract manufacturers, and distributors that operate across transnational supply chains. Tariff changes can alter the relative cost structure of active pharmaceutical ingredients and excipients sourced from international suppliers, prompting firms to reassess supplier diversification, nearshoring, and stockpiling strategies. For brain cancer therapeutics-many of which rely on specialized raw materials, biologic components, or device-related delivery systems-any incremental input cost can cascade through manufacturing schedules and contractual pricing structures.

Moreover, tariffs have implications for clinical trial logistics and the movement of investigational medicinal products between study sites, potentially increasing administrative overhead and necessitating earlier contingency planning. Payers and procurement teams may respond to altered cost baselines by tightening formularies or emphasizing cost-effectiveness data, which underscores the importance of demonstrating differential clinical value. In response, industry players are pursuing strategies such as renegotiating supplier agreements, transferring select manufacturing steps to tariff-favored jurisdictions, and accelerating localization of critical inputs. Ultimately, the net effect is an increased premium on supply chain resilience and strategic sourcing decisions, with successful organizations prioritizing flexibility and transparent cost modeling to mitigate tariff-driven disruptions.

Insights Derived from Segmentation by Indication, Drug Class, Administration Route, End User, and Distribution Channel That Inform Strategic Priorities

Segmentation by indication clarifies heterogeneity in clinical need and development emphasis, with glioblastoma multiforme representing persistent unmet needs due to its aggressive biology, while meningioma, metastatic brain tumors, and pituitary tumors each require distinct therapeutic approaches and regulatory pathways. Understanding those clinical distinctions sharpens target selection and trial design. Segmentation by drug class highlights that chemotherapy remains a foundational backbone in some regimens, with alkylating agents, antimetabolites, and plant alkaloids delivering cytotoxic mechanisms. Meanwhile, immunotherapy modalities such as cancer vaccines, CAR-T therapy, and checkpoint inhibitors offer immune-mediated strategies that may provide durable responses in selected cohorts. Supportive therapy components like anti-emetics and growth factors play a critical role in maintaining dose intensity and patient quality of life. Targeted therapies, including monoclonal antibodies and tyrosine kinase inhibitors, enable precision targeting of oncogenic drivers and signaling pathways.

Route of administration segmentation-intrathecal, intravenous, and oral-drives considerations around formulation development, patient adherence, and facility requirements, and it informs decisions on outpatient versus inpatient delivery models. End user segmentation across clinics, home healthcare, and hospitals shapes operational planning for infusion capacity, home administration protocols, and training needs for multidisciplinary teams. Distribution channel segmentation differentiates hospital pharmacies, online pharmacies, and retail pharmacies, each presenting unique compliance, cold chain, and reimbursement touchpoints that influence market access strategies. By integrating these segment lenses, stakeholders can prioritize resource allocation, refine clinical development plans, and align commercialization approaches with the operational realities of delivery and access.

Regional Dynamics and Competitive Contexts Across the Americas, Europe, Middle East & Africa, and Asia-Pacific That Shape Market Entry and Partnership Strategies

Regional dynamics vary substantially, driven by differences in regulatory frameworks, reimbursement architectures, clinical research capacity, and healthcare infrastructure. In the Americas, established centers of excellence and robust clinical trial networks support early adoption of novel therapeutics and facilitate rapid patient accrual, while payers increasingly demand real-world outcome evidence. In Europe, Middle East & Africa, regulatory harmonization efforts and national health technology assessment processes require nuanced market access planning and long-term health economic modeling to secure formulary inclusion. In Asia-Pacific, rapid investments in oncology research, expanding hospital capacity, and growing local manufacturing capabilities present both scale opportunities and complexity related to heterogeneous regulatory pathways and pricing environments.

Across these regions, partnership models differ: collaborations with academic centers and contract research organizations support translational research in advanced markets, while alliances with regional distributors and local manufacturers enable market entry where localized production or regulatory familiarity is advantageous. Clinical adoption is influenced by variations in diagnostic capacity and standard-of-care practices, which can affect the pace of uptake for biomarker-driven therapies. Therefore, region-specific strategies that consider regulatory timing, reimbursement levers, and local clinical practice are essential for effective deployment of brain cancer therapeutics.

Key Company-Level Insights on Capabilities, Strategic Positioning, and Collaboration Models Driving Progress in Brain Cancer Therapeutics

Leading pharmaceutical and biotechnology companies are strengthening capabilities across several domains to sustain momentum in brain cancer therapeutics. R&D investments are increasingly concentrated on platforms that enhance central nervous system penetration, biomarker-driven patient selection, and combination strategies that pair targeted agents with immune modulators. Companies are differentiating through specialized manufacturing competencies, including viral vector and cell therapy production, as well as through strategic partnerships with diagnostic developers to co-develop companion assays that enable precise enrollment and label differentiation.

Collaboration models show a clear trend toward risk-sharing alliances between innovators, contract manufacturing organizations, academic centers, and biotechnology partners. These models facilitate access to niche expertise, accelerate early-phase development, and de-risk later-stage programs. Portfolio strategies favor a balance between novel mechanisms of action and assets that enhance tolerability or extend durability of response. Additionally, business development activity increasingly emphasizes in-licensing of promising early-stage assets and targeted acquisitions that complement delivery technologies or diagnostic capabilities. Overall, successful organizations demonstrate integrated clinical, regulatory, and commercial planning supported by strategic external partnerships.

Actionable Recommendations for Industry Leaders to Strengthen Development Pipelines, Market Access, and Patient-Centered Delivery Models

Industry leaders should prioritize early and iterative engagement with regulatory agencies and payers to align on evidence requirements and acceptable end points that reflect meaningful clinical benefit. Investing in companion diagnostics and standardized biomarker assays will improve trial efficiency and support targeted labeling claims. From an operational perspective, enhancing supply chain redundancy and pursuing regional manufacturing partnerships can mitigate tariff and logistic risks while shortening time-to-clinic for investigational products.

Companies should also design development programs that build robust real-world evidence pathways, including registries and post-approval studies, to support durable reimbursement agreements. Emphasizing tolerability and quality-of-life outcomes alongside efficacy will aid in demonstrating value to clinicians and payers. Collaboration with home healthcare providers and hospitals to develop safe administration protocols will expand access and reduce treatment burden for patients. Finally, adopting flexible commercial models-such as outcome-linked contracting and tailored regional pricing strategies-can facilitate access across diverse healthcare systems while protecting commercial sustainability.

Transparent Research Methodology Explaining Data Sources, Analytic Approaches, and Validation Processes That Underpin the Report's Findings

The research methodology integrates primary and secondary approaches to ensure comprehensive coverage and validation of insights. Primary research comprises structured interviews with clinical investigators, oncology pharmacists, payers, hospital procurement officers, and industry executives, supplemented by advisory board consultations to contextualize practice patterns and adoption barriers. Secondary research includes peer-reviewed literature, regulatory documents, clinical trial registries, conference proceedings, and company disclosures to map technological trends, mechanism of action developments, and regulatory precedents.

Analytical techniques include qualitative thematic analysis to synthesize stakeholder perspectives and quantitative cross-sectional analyses to examine adoption patterns across segments and regions. Triangulation of data sources and iterative validation with subject-matter experts are employed to reduce bias and confirm findings. The methodology acknowledges limitations related to the evolving clinical landscape and potential lag between emerging scientific developments and peer-reviewed evidence, and it emphasizes that conclusions are intended to inform strategic decision-making rather than provide prescriptive clinical guidance.

Concluding Synthesis That Integrates Clinical Promise, Commercial Realities, and Strategic Imperatives for Brain Cancer Drug Stakeholders

In conclusion, the brain cancer therapeutics landscape is characterized by significant scientific promise alongside complex developmental and commercialization challenges. Advances in precision medicine, immunotherapy, and delivery science have expanded the array of plausible therapeutic strategies, but successful translation into widespread clinical practice requires coordinated efforts across clinical development, diagnostics, manufacturing, and payer engagement. Supply chain pressures and tariff dynamics have added urgency to strategic sourcing and regional manufacturing considerations, while regional heterogeneity in regulatory and reimbursement systems demands tailored market access approaches.

To capitalize on emerging opportunities, organizations must combine scientific rigor with pragmatic commercial planning: design biomarker-enabled trials, invest in companion diagnostics and real-world evidence, strengthen manufacturing and distribution resilience, and pursue collaborative alliances that bring complementary capabilities. By aligning clinical innovation with operational excellence and payer-focused evidence generation, stakeholders can improve patient access to meaningful treatments and create sustainable value across the therapeutic ecosystem.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Integration of next-generation sequencing biomarkers in personalized glioma therapy selection
• 5.2. Rising adoption of convection-enhanced delivery systems for localized brain tumor treatments
• 5.3. Development of blood-brain barrier-penetrating small molecule inhibitors for recurrent glioblastoma
• 5.4. Clinical advancement of oncolytic virus therapies combined with immune checkpoint inhibitors in brain cancer
• 5.5. Investment surge in bispecific antibody constructs targeting multiple glioma antigens for improved outcomes
• 5.6. Deployment of artificial intelligence algorithms to optimize radiotherapy planning and monitoring in brain tumors

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Brain Cancer Drugs Market, by Indication

• 8.1. Glioblastoma Multiforme
• 8.2. Meningioma
• 8.3. Metastatic Brain Tumors
• 8.4. Pituitary Tumors

9. Brain Cancer Drugs Market, by Drug Class

• 9.1. Chemotherapy
  • 9.1.1. Alkylating Agents
  • 9.1.2. Antimetabolites
  • 9.1.3. Plant Alkaloids
• 9.2. Immunotherapy
  • 9.2.1. Cancer Vaccines
  • 9.2.2. CAR-T Therapy
  • 9.2.3. Checkpoint Inhibitors
• 9.3. Supportive Therapy
  • 9.3.1. Anti-Emetics
  • 9.3.2. Growth Factors
• 9.4. Targeted Therapy
  • 9.4.1. Monoclonal Antibodies
  • 9.4.2. Tyrosine Kinase Inhibitors

10. Brain Cancer Drugs Market, by Route Of Administration

• 10.1. Intrathecal
• 10.2. Intravenous
• 10.3. Oral

11. Brain Cancer Drugs Market, by End User

• 11.1. Clinics
• 11.2. Home Healthcare
• 11.3. Hospitals

12. Brain Cancer Drugs Market, by Distribution Channel

• 12.1. Hospital Pharmacies
• 12.2. Online Pharmacies
• 12.3. Retail Pharmacies

13. Brain Cancer Drugs Market, by Region

• 13.1. Americas
  • 13.1.1. North America
  • 13.1.2. Latin America
• 13.2. Europe, Middle East & Africa
  • 13.2.1. Europe
  • 13.2.2. Middle East
  • 13.2.3. Africa
• 13.3. Asia-Pacific

14. Brain Cancer Drugs Market, by Group

• 14.1. ASEAN
• 14.2. GCC
• 14.3. European Union
• 14.4. BRICS
• 14.5. G7
• 14.6. NATO

15. Brain Cancer Drugs Market, by Country

• 15.1. United States
• 15.2. Canada
• 15.3. Mexico
• 15.4. Brazil
• 15.5. United Kingdom
• 15.6. Germany
• 15.7. France
• 15.8. Russia
• 15.9. Italy
• 15.10. Spain
• 15.11. China
• 15.12. India
• 15.13. Japan
• 15.14. Australia
• 15.15. South Korea

16. Competitive Landscape

• 16.1. Market Share Analysis, 2024
• 16.2. FPNV Positioning Matrix, 2024
• 16.3. Competitive Analysis
  • 16.3.1. F. Hoffmann-La Roche Ltd
  • 16.3.2. Merck & Co., Inc.
  • 16.3.3. Bristol-Myers Squibb Company
  • 16.3.4. Novartis AG
  • 16.3.5. Pfizer Inc.
  • 16.3.6. Johnson & Johnson
  • 16.3.7. Bayer Aktiengesellschaft
  • 16.3.8. AbbVie Inc.
  • 16.3.9. Teva Pharmaceutical Industries Ltd
  • 16.3.10. Amgen Inc.

LIST OF FIGURES

• FIGURE 1. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
• FIGURE 2. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY INDICATION, 2024 VS 2032 (%)
• FIGURE 3. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY INDICATION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 4. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2024 VS 2032 (%)
• FIGURE 5. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 6. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2032 (%)
• FIGURE 7. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 8. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY END USER, 2024 VS 2032 (%)
• FIGURE 9. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 10. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
• FIGURE 11. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 12. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 13. AMERICAS BRAIN CANCER DRUGS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 14. NORTH AMERICA BRAIN CANCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 15. LATIN AMERICA BRAIN CANCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 16. EUROPE, MIDDLE EAST & AFRICA BRAIN CANCER DRUGS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 17. EUROPE BRAIN CANCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 18. MIDDLE EAST BRAIN CANCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 19. AFRICA BRAIN CANCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 20. ASIA-PACIFIC BRAIN CANCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 21. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 22. ASEAN BRAIN CANCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 23. GCC BRAIN CANCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 24. EUROPEAN UNION BRAIN CANCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 25. BRICS BRAIN CANCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 26. G7 BRAIN CANCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 27. NATO BRAIN CANCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 28. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 29. BRAIN CANCER DRUGS MARKET SHARE, BY KEY PLAYER, 2024
• FIGURE 30. BRAIN CANCER DRUGS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

• TABLE 1. BRAIN CANCER DRUGS MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
• TABLE 3. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, 2018-2024 (USD MILLION)
• TABLE 4. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, 2025-2032 (USD MILLION)
• TABLE 5. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
• TABLE 6. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
• TABLE 7. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY GLIOBLASTOMA MULTIFORME, BY REGION, 2018-2024 (USD MILLION)
• TABLE 8. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY GLIOBLASTOMA MULTIFORME, BY REGION, 2025-2032 (USD MILLION)
• TABLE 9. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY GLIOBLASTOMA MULTIFORME, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 10. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY GLIOBLASTOMA MULTIFORME, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 11. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY GLIOBLASTOMA MULTIFORME, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 12. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY GLIOBLASTOMA MULTIFORME, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 13. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY MENINGIOMA, BY REGION, 2018-2024 (USD MILLION)
• TABLE 14. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY MENINGIOMA, BY REGION, 2025-2032 (USD MILLION)
• TABLE 15. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY MENINGIOMA, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 16. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY MENINGIOMA, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 17. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY MENINGIOMA, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 18. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY MENINGIOMA, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 19. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY METASTATIC BRAIN TUMORS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 20. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY METASTATIC BRAIN TUMORS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 21. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY METASTATIC BRAIN TUMORS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 22. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY METASTATIC BRAIN TUMORS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 23. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY METASTATIC BRAIN TUMORS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 24. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY METASTATIC BRAIN TUMORS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 25. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY PITUITARY TUMORS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 26. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY PITUITARY TUMORS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 27. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY PITUITARY TUMORS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 28. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY PITUITARY TUMORS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 29. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY PITUITARY TUMORS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 30. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY PITUITARY TUMORS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 31. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
• TABLE 32. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
• TABLE 33. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
• TABLE 34. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2025-2032 (USD MILLION)
• TABLE 35. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
• TABLE 36. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2025-2032 (USD MILLION)
• TABLE 37. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 38. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 39. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 40. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 41. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY ALKYLATING AGENTS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 42. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY ALKYLATING AGENTS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 43. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY ALKYLATING AGENTS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 44. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY ALKYLATING AGENTS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 45. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY ALKYLATING AGENTS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 46. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY ALKYLATING AGENTS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 47. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY ANTIMETABOLITES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 48. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY ANTIMETABOLITES, BY REGION, 2025-2032 (USD MILLION)
• TABLE 49. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY ANTIMETABOLITES, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 50. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY ANTIMETABOLITES, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 51. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY ANTIMETABOLITES, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 52. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY ANTIMETABOLITES, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 53. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY PLANT ALKALOIDS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 54. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY PLANT ALKALOIDS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 55. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY PLANT ALKALOIDS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 56. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY PLANT ALKALOIDS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 57. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY PLANT ALKALOIDS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 58. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY PLANT ALKALOIDS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 59. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
• TABLE 60. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2025-2032 (USD MILLION)
• TABLE 61. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
• TABLE 62. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2025-2032 (USD MILLION)
• TABLE 63. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 64. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 65. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 66. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 67. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY CANCER VACCINES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 68. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY CANCER VACCINES, BY REGION, 2025-2032 (USD MILLION)
• TABLE 69. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY CANCER VACCINES, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 70. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY CANCER VACCINES, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 71. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY CANCER VACCINES, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 72. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY CANCER VACCINES, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 73. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY CAR-T THERAPY, BY REGION, 2018-2024 (USD MILLION)
• TABLE 74. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY CAR-T THERAPY, BY REGION, 2025-2032 (USD MILLION)
• TABLE 75. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY CAR-T THERAPY, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 76. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY CAR-T THERAPY, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 77. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY CAR-T THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 78. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY CAR-T THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 79. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY CHECKPOINT INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 80. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY CHECKPOINT INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 81. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY CHECKPOINT INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 82. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY CHECKPOINT INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 83. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY CHECKPOINT INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 84. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY CHECKPOINT INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 85. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY SUPPORTIVE THERAPY, 2018-2024 (USD MILLION)
• TABLE 86. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY SUPPORTIVE THERAPY, 2025-2032 (USD MILLION)
• TABLE 87. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY SUPPORTIVE THERAPY, BY REGION, 2018-2024 (USD MILLION)
• TABLE 88. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY SUPPORTIVE THERAPY, BY REGION, 2025-2032 (USD MILLION)
• TABLE 89. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY SUPPORTIVE THERAPY, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 90. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY SUPPORTIVE THERAPY, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 91. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY SUPPORTIVE THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 92. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY SUPPORTIVE THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 93. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY ANTI-EMETICS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 94. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY ANTI-EMETICS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 95. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY ANTI-EMETICS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 96. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY ANTI-EMETICS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 97. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY ANTI-EMETICS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 98. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY ANTI-EMETICS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 99. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY GROWTH FACTORS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 100. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY GROWTH FACTORS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 101. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY GROWTH FACTORS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 102. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY GROWTH FACTORS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 103. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY GROWTH FACTORS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 104. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY GROWTH FACTORS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 105. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
• TABLE 106. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2025-2032 (USD MILLION)
• TABLE 107. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2018-2024 (USD MILLION)
• TABLE 108. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2025-2032 (USD MILLION)
• TABLE 109. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 110. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 111. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 112. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 113. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 114. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2025-2032 (USD MILLION)
• TABLE 115. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 116. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 117. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 118. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 119. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 120. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 121. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 122. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 123. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 124. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 125. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 126. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
• TABLE 127. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY INTRATHECAL, BY REGION, 2018-2024 (USD MILLION)
• TABLE 128. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY INTRATHECAL, BY REGION, 2025-2032 (USD MILLION)
• TABLE 129. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY INTRATHECAL, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 130. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY INTRATHECAL, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 131. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY INTRATHECAL, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 132. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY INTRATHECAL, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 133. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 134. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 135. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 136. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 137. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 138. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 139. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
• TABLE 140. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY ORAL, BY REGION, 2025-2032 (USD MILLION)
• TABLE 141. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY ORAL, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 142. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY ORAL, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 143. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 144. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY ORAL, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 145. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 146. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 147. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY CLINICS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 148. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY CLINICS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 149. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 150. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 151. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 152. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 153. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY HOME HEALTHCARE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 154. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY HOME HEALTHCARE, BY REGION, 2025-2032 (USD MILLION)
• TABLE 155. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY HOME HEALTHCARE, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 156. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY HOME HEALTHCARE, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 157. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY HOME HEALTHCARE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 158. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY HOME HEALTHCARE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 159. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 160. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 161. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 162. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 163. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 164. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 165. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 166. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 167. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 168. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
• TABLE 169. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 170. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 171. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 172. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 173. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 174. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
• TABLE 175. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 176. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 177. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 178. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 179. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 180. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
• TABLE 181. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 182. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 183. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 184. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 185. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 186. GLOBAL BRAIN CANCER DRUGS MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
• TABLE 187. AMERICAS BRAIN CANCER DRUGS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
• TABLE 188. AMERICAS BRAIN CANCER DRUGS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
• TABLE 189. AMERICAS BRAIN CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
• TABLE 190. AMERICAS BRAIN CANCER DRUGS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
• TABLE 191. AMERICAS BRAIN CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
• TABLE 192. AMERICAS BRAIN CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
• TABLE 193. AMERICAS BRAIN CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
• TABLE 194. AMERICAS BRAIN CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2025-2032 (USD MILLION)
• TABLE 195. AMERICAS BRAIN CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
• TABLE 196. AMERICAS BRAIN CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2025-2032 (USD MILLION)
• TABLE 197. AMERICAS BRAIN CANCER DRUGS MARKET SIZE, BY SUPPORTIVE THERAPY, 2018-2024 (USD MILLION)
• TABLE 198. AMERICAS BRAIN CANCER DRUGS MARKET SIZE, BY SUPPORTIVE THERAPY, 2025-2032 (USD MILLION)
• TABLE 199. AMERICAS BRAIN CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
• TABLE 200. AMERICAS BRAIN CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2025-2032 (USD MILLION)
• TABLE 201. AMERICAS BRAIN CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 202. AMERICAS BRAIN CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
• TABLE 203. AMERICAS BRAIN CANCER DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 204. AMERICAS BRAIN CANCER DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 205. AMERICAS BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 206. AMERICAS BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 207. NORTH AMERICA BRAIN CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 208. NORTH AMERICA BRAIN CANCER DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 209. NORTH AMERICA BRAIN CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
• TABLE 210. NORTH AMERICA BRAIN CANCER DRUGS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
• TABLE 211. NORTH AMERICA BRAIN CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
• TABLE 212. NORTH AMERICA BRAIN CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
• TABLE 213. NORTH AMERICA BRAIN CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
• TABLE 214. NORTH AMERICA BRAIN CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2025-2032 (USD MILLION)
• TABLE 215. NORTH AMERICA BRAIN CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
• TABLE 216. NORTH AMERICA BRAIN CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2025-2032 (USD MILLION)
• TABLE 217. NORTH AMERICA BRAIN CANCER DRUGS MARKET SIZE, BY SUPPORTIVE THERAPY, 2018-2024 (USD MILLION)
• TABLE 218. NORTH AMERICA BRAIN CANCER DRUGS MARKET SIZE, BY SUPPORTIVE THERAPY, 2025-2032 (USD MILLION)
• TABLE 219. NORTH AMERICA BRAIN CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
• TABLE 220. NORTH AMERICA BRAIN CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2025-2032 (USD MILLION)
• TABLE 221. NORTH AMERICA BRAIN CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 222. NORTH AMERICA BRAIN CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
• TABLE 223. NORTH AMERICA BRAIN CANCER DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 224. NORTH AMERICA BRAIN CANCER DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 225. NORTH AMERICA BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 226. NORTH AMERICA BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 227. LATIN AMERICA BRAIN CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 228. LATIN AMERICA BRAIN CANCER DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 229. LATIN AMERICA BRAIN CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
• TABLE 230. LATIN AMERICA BRAIN CANCER DRUGS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
• TABLE 231. LATIN AMERICA BRAIN CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
• TABLE 232. LATIN AMERICA BRAIN CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
• TABLE 233. LATIN AMERICA BRAIN CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
• TABLE 234. LATIN AMERICA BRAIN CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2025-2032 (USD MILLION)
• TABLE 235. LATIN AMERICA BRAIN CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
• TABLE 236. LATIN AMERICA BRAIN CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2025-2032 (USD MILLION)
• TABLE 237. LATIN AMERICA BRAIN CANCER DRUGS MARKET SIZE, BY SUPPORTIVE THERAPY, 2018-2024 (USD MILLION)
• TABLE 238. LATIN AMERICA BRAIN CANCER DRUGS MARKET SIZE, BY SUPPORTIVE THERAPY, 2025-2032 (USD MILLION)
• TABLE 239. LATIN AMERICA BRAIN CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
• TABLE 240. LATIN AMERICA BRAIN CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2025-2032 (USD MILLION)
• TABLE 241. LATIN AMERICA BRAIN CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 242. LATIN AMERICA BRAIN CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
• TABLE 243. LATIN AMERICA BRAIN CANCER DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 244. LATIN AMERICA BRAIN CANCER DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 245. LATIN AMERICA BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 246. LATIN AMERICA BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 247. EUROPE, MIDDLE EAST & AFRICA BRAIN CANCER DRUGS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
• TABLE 248. EUROPE, MIDDLE EAST & AFRICA BRAIN CANCER DRUGS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
• TABLE 249. EUROPE, MIDDLE EAST & AFRICA BRAIN CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
• TABLE 250. EUROPE, MIDDLE EAST & AFRICA BRAIN CANCER DRUGS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
• TABLE 251. EUROPE, MIDDLE EAST & AFRICA BRAIN CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
• TABLE 252. EUROPE, MIDDLE EAST & AFRICA BRAIN CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
• TABLE 253. EUROPE, MIDDLE EAST & AFRICA BRAIN CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
• TABLE 254. EUROPE, MIDDLE EAST & AFRICA BRAIN CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2025-2032 (USD MILLION)
• TABLE 255. EUROPE, MIDDLE EAST & AFRICA BRAIN CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
• TABLE 256. EUROPE, MIDDLE EAST & AFRICA BRAIN CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2025-2032 (USD MILLION)
• TABLE 257. EUROPE, MIDDLE EAST & AFRICA BRAIN CANCER DRUGS MARKET SIZE, BY SUPPORTIVE THERAPY, 2018-2024 (USD MILLION)
• TABLE 258. EUROPE, MIDDLE EAST & AFRICA BRAIN CANCER DRUGS MARKET SIZE, BY SUPPORTIVE THERAPY, 2025-2032 (USD MILLION)
• TABLE 259. EUROPE, MIDDLE EAST & AFRICA BRAIN CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
• TABLE 260. EUROPE, MIDDLE EAST & AFRICA BRAIN CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2025-2032 (USD MILLION)
• TABLE 261. EUROPE, MIDDLE EAST & AFRICA BRAIN CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 262. EUROPE, MIDDLE EAST & AFRICA BRAIN CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
• TABLE 263. EUROPE, MIDDLE EAST & AFRICA BRAIN CANCER DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 264. EUROPE, MIDDLE EAST & AFRICA BRAIN CANCER DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 265. EUROPE, MIDDLE EAST & AFRICA BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 266. EUROPE, MIDDLE EAST & AFRICA BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 267. EUROPE BRAIN CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 268. EUROPE BRAIN CANCER DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 269. EUROPE BRAIN CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
• TABLE 270. EUROPE BRAIN CANCER DRUGS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
• TABLE 271. EUROPE BRAIN CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
• TABLE 272. EUROPE BRAIN CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
• TABLE 273. EUROPE BRAIN CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
• TABLE 274. EUROPE BRAIN CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2025-2032 (USD MILLION)
• TABLE 275. EUROPE BRAIN CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
• TABLE 276. EUROPE BRAIN CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2025-2032 (USD MILLION)
• TABLE 277. EUROPE BRAIN CANCER DRUGS MARKET SIZE, BY SUPPORTIVE THERAPY, 2018-2024 (USD MILLION)
• TABLE 278. EUROPE BRAIN CANCER DRUGS MARKET SIZE, BY SUPPORTIVE THERAPY, 2025-2032 (USD MILLION)
• TABLE 279. EUROPE BRAIN CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
• TABLE 280. EUROPE BRAIN CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2025-2032 (USD MILLION)
• TABLE 281. EUROPE BRAIN CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 282. EUROPE BRAIN CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
• TABLE 283. EUROPE BRAIN CANCER DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 284. EUROPE BRAIN CANCER DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 285. EUROPE BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 286. EUROPE BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 287. MIDDLE EAST BRAIN CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 288. MIDDLE EAST BRAIN CANCER DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 289. MIDDLE EAST BRAIN CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
• TABLE 290. MIDDLE EAST BRAIN CANCER DRUGS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
• TABLE 291. MIDDLE EAST BRAIN CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
• TABLE 292. MIDDLE EAST BRAIN CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
• TABLE 293. MIDDLE EAST BRAIN CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
• TABLE 294. MIDDLE EAST BRAIN CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2025-2032 (USD MILLION)
• TABLE 295. MIDDLE EAST BRAIN CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
• TABLE 296. MIDDLE EAST BRAIN CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2025-2032 (USD MILLION)
• TABLE 297. MIDDLE EAST BRAIN CANCER DRUGS MARKET SIZE, BY SUPPORTIVE THERAPY, 2018-2024 (USD MILLION)
• TABLE 298. MIDDLE EAST BRAIN CANCER DRUGS MARKET SIZE, BY SUPPORTIVE THERAPY, 2025-2032 (USD MILLION)
• TABLE 299. MIDDLE EAST BRAIN CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
• TABLE 300. MIDDLE EAST BRAIN CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2025-2032 (USD MILLION)
• TABLE 301. MIDDLE EAST BRAIN CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 302. MIDDLE EAST BRAIN CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
• TABLE 303. MIDDLE EAST BRAIN CANCER DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 304. MIDDLE EAST BRAIN CANCER DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 305. MIDDLE EAST BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 306. MIDDLE EAST BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 307. AFRICA BRAIN CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 308. AFRICA BRAIN CANCER DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 309. AFRICA BRAIN CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
• TABLE 310. AFRICA BRAIN CANCER DRUGS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
• TABLE 311. AFRICA BRAIN CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
• TABLE 312. AFRICA BRAIN CANCER DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
• TABLE 313. AFRICA BRAIN CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
• TABLE 314. AFRICA BRAIN CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2025-2032 (USD MILLION)
• TABLE 315. AFRICA BRAIN CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
• TABLE 316. AFRICA BRAIN CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2025-2032 (USD MILLION)
• TABLE 317. AFRICA BRAIN CANCER DRUGS MARKET SIZE, BY SUPPORTIVE THERAPY, 2018-2024 (USD MILLION)
• TABLE 318. AFRICA BRAIN CANCER DRUGS MARKET SIZE, BY SUPPORTIVE THERAPY, 2025-2032 (USD MILLION)
• TABLE 319. AFRICA BRAIN CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
• TABLE 320. AFRICA BRAIN CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2025-2032 (USD MILLION)
• TABLE 321. AFRICA BRAIN CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 322. AFRICA BRAIN CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
• TABLE 323. AFRICA BRAIN CANCER DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 324. AFRICA BRAIN CANCER DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 325. AFRICA BRAIN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION C